EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond

Anthony Cheung, Yi Liu, Alicia M Chenoweth, Hanieh Montaseri, Benjamina Esapa, Vijay Chudasama, James R Baker, David E Thurston, Sophia N Karagiannis iD

Physiological Reviews · 01.07.2026 · 106 (3) · 1681-1756

DOI: 10.1152/physrev.00039.2025 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Physiological Reviews, erschienen am 01.07.2026. Verfasst von Anthony Cheung und 8 weiteren Autor:innen. Beteiligte Einrichtung: Breast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, King's College London, Innovation Hub, Guy's Hospital, London, United …. Hauptthemen laut MEDLINE: Immunoconjugates, Neoplasms, Drug Design, Antineoplastic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 594 Literaturangaben. Gefördert von: Breast Cancer Now (BCN), Cancer Research UK (CRUK), Worldwide Cancer Research (WCR).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody-drug conjugates (ADCs) are a leading area of targeted cancer therapeutics, typically combining a tumor-associated antigen-specific antibody conjugated to a toxic payload that targets key cellular mechanisms, such as mitosis and survival. The global ADC clinical trial landscape has been expanding significantly, with over 430 ADCs reaching early to late clinical studies in the past two decades, up from just 90 between 2004 and 2014. The US Food and Drug Administration (FDA) has so far approved 14 ADCs for use in clinical oncology. This growth is likely driven by significant advances in antibody technology and conjugation methods enabling more effective and precise delivery to cancer cells and more effective payloads that target vital cancer biology. Here, we review the ADCs that have reached clinical approval as well as current and emerging trends in ADC development, and we discuss these from multiple perspectives, including ADC mechanisms of action, emerging antigen targets, linker and conjugation chemistry, payloads, combination of ADC with checkpoint inhibitor immunotherapy, and antibody fragment crystallizable (Fc) engineering. We also consider how the field is evolving through the application of artificial intelligence (AI) and pathology-based biomarker discovery. Combined, innovative and emerging ADC design coupled with precision medicine and patient stratification strategies hold great promise to develop diverse and personalized cancer treatments with improved therapeutic indices and to enhance tolerability compared to traditional chemotherapy and current established ADCs. This review aims to assist researchers in exploring the evolution, characteristics, and development trends in ADC design and to provide new directions for future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesNeoplasmsDrug DesignAntineoplastic AgentsAntineoplastic Agents, ImmunologicalHumansAnimals

Stichwörter der Autor:innen

ADCantibodyantibody-drug conjugatecancerpayload

Substanzen

ImmunoconjugatesAntineoplastic AgentsAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Breast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, King's College London, Innovation Hub, Guy's Hospital, London, United Kingdom.
  • St. John's Institute of Dermatology, School of Basic and Medical Biosciences and King's Health Partners Centre for Translational Medicine, Guy's Hospital, King's College London, London, United Kingdom.
  • Department of Chemistry, University College London, London, United Kingdom.
  • Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Sciences, King's College London, London, United Kingdom.

ORCID-Profile: Sophia N Karagiannis

Förderung

  • Breast Cancer Now (BCN)
  • Cancer Research UK (CRUK)
  • Worldwide Cancer Research (WCR)
  • British Skin Foundation (BSF)
  • Wellbeing of Women
  • King's Health Partners | Guy's and St Thomas' NHS Foundation Trust
  • UKRI | Medical Research Council (MRC)

Zitieren

APA

Cheung, A., Liu, Y., Chenoweth, A. M., Montaseri, H., Esapa, B., Chudasama, V., Baker, J. R., Thurston, D. E., & Karagiannis, S. N. (2026). Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond. Physiological Reviews, 106(3), 1681-1756. https://doi.org/10.1152/physrev.00039.2025

Vancouver

Cheung A, Liu Y, Chenoweth AM, Montaseri H, Esapa B, Chudasama V, et al. Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond. Physiological Reviews. 2026;106(3):1681-1756. doi:10.1152/physrev.00039.2025

BibTeX
@article{Cheung2026,
  author = {Cheung, Anthony and Liu, Yi and Chenoweth, Alicia M and Montaseri, Hanieh and Esapa, Benjamina and Chudasama, Vijay and Baker, James R and Thurston, David E and Karagiannis, Sophia N},
  title = {Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond},
  journal = {Physiological Reviews},
  year = {2026},
  volume = {106},
  number = {3},
  pages = {1681--1756},
  doi = {10.1152/physrev.00039.2025}
}
Kostenlos starten →